Disease Competitive Landscape Monitoring

Acute myelogenous leukemia (AML) Disease Landscape provides comprehensive market intelligence with epidemiology, keen insight into current treatment paradigms, in-depth pipeline coverage ( ~ 500 unique industry-sponsored studies) and clinical trial landscape supported by detailed recent results from ASH 2022, ASCO 2022 and EHA 2022. The drugs are further classified according to the class of therapies: antibody drug conjugates, bispecific antibodies, tri-specific and monoclonal antibodies, CAR-T therapies & T cells therapies, vaccines, small molecules and others.